title: Outcome of fibrillary glomerulonephritis.
abstract: OBJECTIVE
  We assessed the long-term follow up of all the patients with fibrillary glomerulonephritis diagnosed since 1992 at our centre of reference for renal pathology in Basel.
  
  
  METHODS
  We performed a retrospective surveillance study with mail questionnaire based follow-up of all patients with the diagnosis of fibrillary glomerulonephritis found in the database of the department of renal pathology in Basel from 1992 to 2007. The outcome was assessed in terms of endstage renal disease (ESRD), death, reduction of proteinuria and improvement of estimated glomerular filtration rate (eGFR).
  
  
  RESULTS
  We obtained sufficient follow up data from 16 out of 20 identified patients. The mean follow up time was 35 months (1-115.1). Six patients died (37.5%), three without having ESRD. Six patients (37.5%) reached ESRD, five of them went on hemodialysis. Thirteen patients (81.3%) received an immunosuppressive therapy with steroids, five of them in combination with cyclophosphamide. The group without immunosuppressive therapy was too small to compare the two groups. In relation to the histological pattern membranous glomerulonephritis (MGN) had a better outcome as compared to the other histological patterns.
  
  
  CONCLUSIONS
  FGN is a heterogeneous disease associated with significant risk of ESRD and mortality. The histological type of the glomerulonephritis may influence the course of the disease.
authors.affiliation: Department of Nephrology, Kantonsspital Liestal, Switzerland. stefan.kalbermatter@ksli.ch
authors.forename: Stefan A
authors.initials: SA
authors.lastname: Kalbermatter
authors.forename: Claudio
authors.initials: C
authors.lastname: Marone
authors.forename: Donatella
authors.initials: D
authors.lastname: Casartelli
authors.forename: Martin
authors.initials: M
authors.lastname: Hausberg
authors.forename: Giovanni
authors.initials: G
authors.lastname: Banfi
authors.forename: Michael
authors.initials: M
authors.lastname: Mihatsch
authors.forename: Michael
authors.initials: M
authors.lastname: Dickenmann
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D003520:Cyclophosphamide / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D005921:Glomerulonephritis / Q000150:complications / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D018709:Statistics, Nonparametric; D013256:Steroids / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D013256:Steroids; D003520:Cyclophosphamide